Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Blood Dendritic Cell Antigen 2 (BDCA-2)
- Target
- BDCA-2
- Molecular classification
- C-type lectin, Type II transmembrane glycoprotein, Receptor
01
Overview
CD303, also known as BDCA-2, is a type II transmembrane glycoprotein and a member of the C-type lectin superfamily. It is exclusively expressed on human plasmacytoid dendritic cells (pDCs) and plays a crucial role in antigen capture and the negative regulation of type I interferon production. CD303 signals via association with the FcεRIγ adaptor protein, leading to the recruitment and phosphorylation of spleen tyrosine kinase (SYK). Targeting CD303 is being explored as a therapeutic strategy for autoimmune diseases and cancer.
- Other names
- CLEC4CDLECCLECSF11HECLCLECSF11/7
02
Mechanism of action
Antibody targeting against CD303 can suppress excessive type I interferon production by crosslinking, engagement, or through complement-dependent cytotoxicity.
03
Biological functions
Antigen captureRegulation of interferon productionImmune response
04
Disease associations
Autoimmune diseasesSystemic lupus erythematosusCancer
05
Safety considerations
Potential for immune suppressionOff-target effects on other immune cells
06
Biomarkers
pDC marker
Beyond the preview
Go deeper on Blood Dendritic Cell Antigen 2 (BDCA-2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blood Dendritic Cell Antigen 2 (BDCA-2).